Medigen Vaccine Biologics Corporation filed new drug application MVC Quadrivalent Influenza Vaccine to Taiwan Food and Drug Administration. New drug name or code: MVC FLU Quadrivalent pre-filled syringe injection. Indication: Prevention of influenza-related diseases caused by two types of influenza A and two types of influenza B viruses.

Planned development stages: File New Drug Application (NDA) to Taiwan Food and Drug Administration. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): File New Drug Application (NDA) to Taiwan Food and Drug Administration; Accumulated investment expenditure incurred: Based on business strategy considerations, it will not be disclosed for the time being.